Podocon-25

Drug overview for PODOCON-25 (podophyllum resin):

Generic name: PODOPHYLLUM RESIN
Drug class:
Therapeutic class: Dermatological

Podophyllum resin, also known as podophyllin, is an antimitotic and caustic agent.

Podophyllum resin is used topically for the treatment of external genital and perianal exophytic warts (condylomata acuminata) caused by human papillomavirus (HPV). The drug also is recommended for the treatment of urethral HPV warts+ , but is not recommended for the treatment of vaginal, cervical, anal, or rectal HPV warts. Podophyllum resin should not be used to treat subclinical genital HPV infection (without exophytic warts). Podophyllum resin has been used topically for the treatment of verruca vulgaris+ (common warts).

DRUG IMAGES

No Image Available

The following indications for PODOCON-25 (podophyllum resin) have been approved by the FDA:

Indications:
External condylomata acuminata
Keratoderma

Professional Synonyms:
External condyloma acuminatum

The following dosing information is available for PODOCON-25 (podophyllum resin):

Dosing
Administration
Dosing Information
Generic

No enhanced Dosing information available for this drug.

Podophyllum resin is applied topically. The drug usually is applied in the form of a 10-25% solution in compound benzoin tincture; the CDC, at least one manufacturer, and other experts recommend that these solutions only be applied by a health-care provider and not dispensed to the patient. Solutions containing lower concentrations of podophyllum resin (i.e., 0.5-2% ethanolic solutions) have been prepared extemporaneously for self-administration by patients+; however, safety and efficacy of these solutions have not been established.

Prior to application of podophyllum resin solution, the affected area should be thoroughly cleansed. The solution should then be applied sparingly to lesions, avoiding contact with normal tissue, and allowed to air dry. The skin adjacent to the area being treated may be protected by applying petrolatum or flexible collodion prior to application of the drug.

Use of large amounts of the drug should be avoided, since systemic toxicity may occur. Immediately after the prescribed period of treatment (usually 1-4 hours), the dried drug should be thoroughly removed from the area of application using alcohol or soap and water. Care must be taken to ensure that all of the drug has been removed.

To determine the patient's sensitivity to the drug, the manufacturer of Podocon-25(R) recommends that the drug be removed within 30-40 minutes after the initial application; for subsequent application, the drug should be removed after the minimum time period required to produce the desired result (usually 1-4 hours). Warts generally become blanched within a few hours after application of the drug and become necrotic within 24-48 hours. After about 72 hours, the lesions begin to slough and gradually disappear without scarring.

No dosing information available.

No generic dosing information available.

Contraindication List
Diabetes mellitus
Pregnancy

Severe List
Bleeding warts

More Frequent	Less Frequent
None.	Erythema Paresthesia Pruritus of skin Skin irritation Skin rash

Rare/Very Rare
None.

The following precautions are available for PODOCON-25 (podophyllum resin):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

Podophyllum resin is contraindicated during pregnancy. Use of topical podophyllum resin during pregnancy has been associated with complications including birth defects, fetal death, and stillbirth. Intrauterine death has occurred following topical application of podophyllum resin to vulval warts during the 32nd week of pregnancy.

Following topical application of the drug during the 23rd, 24th, 25th, 28th, and 29th weeks of pregnancy in one woman, minor fetal anomalies including preauricular skin tags and a simian crease on the left hand occurred. Following oral administration during pregnancy of a preparation containing podophyllum, possible adverse fetal effects of the drug have included skin tags on the ear and cheek, polyneuritis, limb malformations, and septal heart defects.

It is not known whether topically applied podophyllum resin is distributed into human milk. The drug is contraindicated in women who are breast-feeding.

No enhanced Geriatric Use information available for this drug.

External condylomata acuminata
A63.0	Anogenital (venereal) warts
Keratoderma
L85.1	Acquired keratosis [keratoderma] palmaris et plantaris